6th Sep 2021 06:22
(Alliance News) - Amgen Inc on Sunday said an asthma drug it's developing with AstraZeneca PLC was shown to be effective in a phase three trial.
Tezepelumab reduced exacerbations by 86% in patients with severe asthma and comorbid nasal polyps, as well as improving lung function and nasal symptoms, in the Navigator trial.
"These results further strengthen our confidence in tezepelumab's potential to address a significant unmet need across a broad population of patients with severe asthma, including those with comorbid nasal polyps. We look forward to bringing this potentially transformative treatment to patients soon," Amgen Vice President of Research and Development David Reese said.
The Thousand Oaks, California-based pharmaceutical firm added that there are 2.5 million patients with severe asthma who are uncontrolled or eligible for biologic treatment, 1 million of them in the US.
Shares in Amgen closed 0.2% higher at USD226.37 on Friday in New York.
By Ivan Edwards; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca